Patents Examined by Anne M. Gussow
  • Patent number: 10287590
    Abstract: The invention provides methods for introducing co-varying paired nucleic acids into a vector such under separate transcriptional control. An oligonucleotide is synthesized including the paired nucleic acids. The oligonucleotide is then assembled with a spacer nucleic acid encoding a promoter. After assembly the spacer nucleic acid is to one side of the oligonucleotide encoding the paired segments. However, on circularization of the assembled nucleic acid and cleavage between the DNA segments the spacer oligonucleotide and its components now occur between the paired segments. The resulting nucleic acid can now be cloned into a vector with a single step, such that each of the paired nucleic acid segments is linked to its own promoter. The present method can readily be extended to library screening without proportionately increasing the effort.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: May 14, 2019
    Assignee: DNA2.0, INC.
    Inventors: Jeremy Minshull, Sridhar Govindrajan, Kedar Patel
  • Patent number: 9944951
    Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: April 17, 2018
    Assignees: Board of Regents, The University of Texas System, The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
  • Patent number: 8501464
    Abstract: It is described a bidirectional promoter for expression of at least two coding sequences in opposite direction in animal cells; bidirectional expression cassettes; expression constructs; gene transfer expression vectors, and methods for the use thereof.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: August 6, 2013
    Assignee: Ospedale San Raffaele S.r.l.
    Inventors: Luigi Naldini, Mario Amendola, Elisa Vigna
  • Patent number: 8349574
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: January 8, 2013
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Stephen J. Williams
  • Patent number: 8298531
    Abstract: The invention relates to treatment of cancer.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: October 30, 2012
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventor: Harald Mottl
  • Patent number: 8287864
    Abstract: The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 VH (CDRH3), result in improved therapeutic properties, such as decreased dissociation rates, improved CDC activity, improved apoptosis, improved B-cell depletion and improved therapeutic efficacy at very low dosages.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: October 16, 2012
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Chien-Hsing Chang, Hans J. Hansen
  • Patent number: 8278421
    Abstract: The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: October 2, 2012
    Assignee: Xoma Techolology Ltd.
    Inventors: Linda Masat, Marina Roell
  • Patent number: 8278423
    Abstract: The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 2, 2012
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Isabelle Teulon, André Pelegrin
  • Patent number: 8268964
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: September 18, 2012
    Assignee: Dako Denmark A/S
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 8268309
    Abstract: The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: September 18, 2012
    Assignee: Theraclone Sciences, Inc.
    Inventor: Ole Olsen
  • Patent number: 8263076
    Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF?, the dAb comprising an immunoglobulin heavy or light chain variable domain comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: September 11, 2012
    Assignee: Cephalon Australia Pty Ltd.
    Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
  • Patent number: 8263746
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: September 11, 2012
    Assignee: Morphosys AG
    Inventors: Michael Tesar, Ute Jager
  • Patent number: 8263744
    Abstract: An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the VH region, CH region, CL region, VL region, the furm linker and the bouganm toxin. The optimized VB6-845 displays improved recombinant protein expression over the original in an E. coli expression system.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: September 11, 2012
    Assignee: Viventia Biotechnologies Inc.
    Inventors: Jeannick Cizeau, Glen Christopher Macdonald
  • Patent number: 8257715
    Abstract: Compositions comprising a tissue vaccine that include a mixture of heterogeneous tissue obtained from tumors and connective tissues. Vaccines comprising these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition of tumor growth, and particularly prostate tumor growth and cancers. The preparations may be defined as vaccines comprising tumor cells and connective (stromal) tissues derived from xenogeneic animals. Preparations comprising the tissue vaccines are provided using tissue harvested directly from tumors. Methods for preventing de novo development of cancer are also disclosed. A tissue vaccine comprising glutaraldehyde-(GFT) treated tissue prepared from tumor and connective tissue reduces the incidence of autochthonous prostate cancer. A tissue vaccine comprising a potassium thiocyanate extract (PTE) preparation of a tumor and connective tissue is also provided.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: September 4, 2012
    Assignee: University of Notre Dame
    Inventors: Mark A. Suckow, William R. Wolter, Morris Pollard
  • Patent number: 8258268
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: September 4, 2012
    Assignee: Abbott Laboratories
    Inventors: Chengbin Wu, Tariq Ghayur, Richard W. Dixon, Jochen G. Salfeld
  • Patent number: 8236931
    Abstract: An inhibitor of the aggregation of immunoglobulin chains is provided. The inhibitor may comprise or consist of a polypeptide which comprises or consists of (a) an amino acid sequence corresponding to the amino acid sequence of the FR1 region of an immunoglobulin light chain variable domain, or part thereof which includes amino acid residue 12, (b) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of bacterial superantigen Protein L, or part thereof, and/or (c) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of streptococcal protein G, or part thereof, or a variant, fusion or derivative thereof, or a fusion of a variant or derivative thereof which retains the ability of the parent polypeptide to inhibit aggregation of immunoglobulin chains, or domains thereof. Other versions of the inhibitor are also provided.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: August 7, 2012
    Assignee: Glaxo Group Limited
    Inventors: Rudolf M. T. De Wildt, Leo C James, Philip C Jones, Oliver Schon, Gregory Paul Winter
  • Patent number: 8227577
    Abstract: The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: July 24, 2012
    Assignee: Hoffman-La Roche Inc.
    Inventors: Christian Klein, Wolfgang Schaefer
  • Patent number: 8227576
    Abstract: Antibodies that bind human ?-amyloid peptide, methods of treating diseases or disorders characterised by elevated ?-amyloid levels or ?-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: July 24, 2012
    Assignee: Glaxo Group Limited
    Inventors: Stephen Anthony Burbidge, Jonathan Henry Ellis, Susannah K Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden
  • Patent number: 8222373
    Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: July 17, 2012
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Patent number: 8207311
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: June 26, 2012
    Assignee: diaDexus, Inc.
    Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon